XINNA YI: Open Payments
NPI 1528740719 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,572 in 68 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $881 · 2025 $1,572
Food & beverage: $1,572
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 4 | $366 |
| PFIZER INC. | 18 | $287 |
| ABBVIE INC. | 15 | $256 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $226 |
| Madrigal Pharmaceuticals | 7 | $153 |
| Ipsen Biopharmaceuticals, Inc | 3 | $89 |
| QOL Medical, LLC | 3 | $43 |
| Novo Nordisk Inc | 2 | $35 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Lilly USA, LLC | 1 | $25 |
Products named: XIFAXAN, Vemlidy, XELJANZ, REZDIFFRA, LINZESS, Livdelzi, VELSIPITY, IQIRVO.
Industry payments across DC — which companies pay providers there.
